Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status
Authors:
Open Access
- 2 November 2014
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 5 (24) , 12877-12890
Abstract
The presence of cancer stem cells (CSCs) is linked to preexisting or acquired drug resistance and tumor relapse. Therefore, targeting both differentiated tumor cells and CSCs was suggested as an effective approach for non-small cell lung cancer (NSCLC) treatment. After screening of chemotherapeutic agents, tyrosine kinase inhibitors (TKIs) or monoclonal antibody in combination with the putative stem cell killer Salinomycin (SAL), we found Metformin (METF), which modestly exerted a growth inhibitory effect on monolayer cells and alveospheres/CSCs of 5 NSCLC cell lines regardless of their EGFR, KRAS, EML4/ALK and LKB1 status, interacted synergistically with SAL to effectively promote cell death. Inhibition of EGFR (AKT, ERK1/2) and mTOR (p70 s6k) signaling with the combination of METF and SAL can be augmented beyond that achieved using each agent individually. Phospho-kinase assay further suggested the multiple roles of this combination in reducing oncogenic effects of modules, such as ß-catenin, Src family kinases (Src, Lyn, Yes), Chk-2 and FAK. Remarkably, significant reduction of sphere formation was seen under combinatorial treatment in all investigated NSCLC cell lines. In conclusion, METF in combination with SAL could be a promising treatment option for patients with advanced NSCLC irrespective of their EGFR, KRAS, EML4/ALK and LKB1 status.Keywords
This publication has 36 references indexed in Scilit:
- Differential Effects of Drugs Targeting Cancer Stem Cell (CSC) and Non-CSC Populations on Lung Primary Tumors and MetastasisPLOS ONE, 2013
- Salinomycin increases chemosensitivity to the effects of doxorubicin in soft tissue sarcomasBMC Cancer, 2013
- SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cellsOncogenesis, 2013
- Eyes Wide Open: A Critical Review of Sphere-Formation as an Assay for Stem CellsCell Stem Cell, 2011
- Understanding the benefit of metformin use in cancer treatmentBMC Medicine, 2011
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- LKB1 modulates lung cancer differentiation and metastasisNature, 2007
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- The COSMIC (Catalogue of Somatic Mutations in Cancer) database and websiteBritish Journal of Cancer, 2004